News | Ventricular Assist Devices (VAD) | March 09, 2017

Collaboration by Metro Detroit Cardiologists Increases Cardiogenic Shock Survival Rate

Heart attack patients treated with Impella heart pump early have seen an 80 percent survival rate

Metro Detroit cardiologists, increased heart attack survival rate, Impella heart pump, Detroit Cardiogenic Shock Initiative

March 9, 2017 — Metro Detroit cardiologists from five health systems have joined together to increase residents’ survival rate from heart attacks.

The Detroit Cardiogenic Shock Initiative doubled survival rates in patients experiencing a life-threatening side-effect to a heart attack, the group announced recently in Detroit.

“This unprecedented effort shows the powerful advances we can make to save lives by working together in metro Detroit,” said lead investigator William W. O’Neill, M.D., director of the Center for Structural Heart Disease at Henry Ford Health System.

Watch a VIDEO interview with O'Neill at ACC.17  - "Cardiogenic Shock Supported With Impella Shows Good Outcomes."

The initiative addresses cardiogenic shock, a devastating complication of heart attacks. In these patients, the pump function of the heart is severely depressed, causing low blood pressure and vital organs to be deprived of sufficient blood supply. Despite contemporary treatments, about 50 percent of patients experiencing the condition die.

The health systems participating in the initiative have agreed to use a heart pump the size of a straw to keep blood pumping throughout the body. The Impella pump, a U.S. Food and Drug Administration (FDA)-approved device, is inserted through a catheter in the groin into the heart as soon as the patient arrives at the hospital. Doctors then treat the cause of the heart attack, either inserting a stent, removing a clot or taking other necessary action while the tiny pump supports circulation in the rest of the body.

The key difference with this initiative is that the Impella system is placed before standard treatment to fix the blocked artery.

“There is no question in our minds that early circulatory support is critical to improve the chance of a successful outcome in these critically ill patients,” said Simon Dixon, M.D., chair of cardiovascular medicine at Beaumont Hospital, Royal Oak, Mich.

Since the initiative began in July 2016, doctors at the participating hospitals found the approach was the most appropriate way to treat 30 patients who were having a heart attack and showing signs of cardiogenic shock. The treatment resulted in an 80 percent survival rate, compared to the traditional 50 percent survival rate.

“Cardiologists have been trying to move the needle on heart attack survival rate for years; this is a huge success,” said Thomas Lalonde, M.D., chief of cardiology at St. John Hospital in Detroit.

Superior Air-Ground Ambulance Service, Inc. is also supporting the initiative when transporting heart attack patients showing signs of cardiogenic shock.

O’Neill is scheduled to mention the initiative’s results in a presentation at the annual American College of Cardiology (ACC) Scientific Sessions, March 17-19 in Washington, D.C. Cardiologists in Boston, Los Angeles and other cities in the United States are following the initiative closely, to replicate for patients there, O’Neill said.

"This is a chance for a number of excellent programs from southeast Michigan to collaborate for the benefit of our patients," said Arthur Szyniszewski, M.D., cardiologist at Saint Joseph Mercy Health System.

Watch a VIDEO demonstration of how the Impella works.

Read the article “Study Examines Influence of Cardiac Arrest and Cardiogenic Shock on STEMI Patient Outcomes/“

The read article "Study Finds Impella Heart Pump Reduces Kidney Injury Risk During High-Risk PCI."

For more information: www.henryford.com

Related Content

Philips Showcases Integrated Solutions for Cardiovascular Care at TCT 2018
News | Cath Lab | September 20, 2018
At the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, Sept. 21–25 in San Diego, Philips is showcasing...
Sponsored Content | Videos | Cath Lab | September 19, 2018
William O’Neill, M.D., outlines his recent clinical publication of AMICS patients from the Impella Quality (IQ) datab
Videos | Cath Lab | September 14, 2018
A discussion with Nicolas Bevins, Ph.D., vice chair, physics and research, and Jessica Harrington, RCIS.
A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. DAIC staff photo by Dave Fornell

A complex PCI case to revascularize a chronic total occlusion (CTO) at Henry Ford Hospital in Detroit. Complex PCI and CHIP cases are increasing patient volumes in the cath lab and using a minimally invasive approach in patients who otherwise would have been sent for CABG. Pictured is Khaldoon Alaswad, M.D. (right) who is proctoring a fellow in treating CTOs.

Feature | Cath Lab | September 13, 2018 | Artur Kim, Kamran Zamanian
Coronary artery disease (CAD) is a multifaceted disease that demands various approaches in terms of diagnosis and tre
Videos | Cath Lab | August 13, 2018
Jeffrey Schussler, M.D., FACC, FSCAI, FSCCT, FACP, interventional cardiologist at Baylor Scott White Heart and Vascul
Shockwave Launches Coronary Intravascular Lithotripsy in Europe
News | Cath Lab | May 30, 2018
Shockwave Medical recently announced the European commercial availability of Intravascular Lithotripsy (IVL) for...
FFR software on the GE Centricity CVIS. A trial from the 2018 EuroPCR meeting showed FFR improves long-term outcomes.
News | Cath Lab | May 29, 2018
May 29, 2018 — Ongoing controversy exists regarding the role of percutaneous coronary intervention (PCI) for stable c
SCAI Updates Consensus on Length of Stay for Percutaneous Coronary Intervention
News | Cath Lab | May 15, 2018
Revised guidelines incorporating new data on discharge criteria for patients undergoing elective percutaneous coronary...
No Benefit Found Using Sodium Bicarbonate, Acetylcysteine to Prevent Kidney Injury, the result of the PRESERVE Trial to prevent acute kidney injury (AKI), presented at SCAI 2018.  #SCAI, #SCAI2018,
Feature | Cath Lab | May 15, 2018
May 15, 2018 – The large-scale, international randomized PRESERVE clinical trial found high-risk patients for renal c
Angiogram of a STEMI patient.
News | Cath Lab | May 15, 2018
May 15, 2018 — A contemporary, real-world analysis shows lower mortality rates when culprit-only intervention is used
Overlay Init